Publications- Pre-2000 - 2005

Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn Microbiol Infect Dis 2005; 51(1):31-37.

Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005; 49(9):3944-3947.

Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM et al. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother 2005; 49(5):1775-1781.

Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother 2005; 49(1):148-152.

Grasela TH, Fiedler-Kelly J, Walawander CA, Owen JS, Cirincione BB, Reitz KE et al. Challenges in the transition to model-based development. AAPS J 2005; 7(2):E488-E495.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005; 41 Suppl 5:S333-S340.

Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005; 52(3):165-171.

Owens RC, Jr., Bhavnani SM, Ambrose PG. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2005; 51(1):45-49.

Owens RC, Jr., Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 Suppl 2:S144-S157.

Ambrose PG, Anon JB, Owen JS, Van Wart S, McPhee ME, Bhavnani SM et al. Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Clin Infect Dis 2004; 38(11):1513-1520.

Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis 2004; 50(2):95-102.

Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2004; 48(12):4766-4777.

Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003; 47(5):1643-1646.

Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003; 52(3):435-440.

Bhavnani SM, Hammel JP, Forrest A, Jones RN, Ambrose PG. Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens. Clin Infect Dis 2003; 37(3):344-350.

Eden E, Hammel J, Rouhani FN, Brantly ML, Barker AF, Buist AS et al. Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. Chest 2003; 123(3):765-771.

Jones RN, Rubino CM, Bhavnani SM, Ambrose PG. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother 2003; 47(1):292-296.

Ambrose PG, Owens RC, Jr., Garvey MJ, Jones RN. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002; 49(3):445-453.

Apfelbaum JL, Walawander CA, Grasela TH, Wise P, McLeskey C, Roizen MF et al. Eliminating intensive postoperative care in same-day surgery patients using short-acting anesthetics. Anesthesiology 2002; 97(1):66-74.

Bhavnani SM, Ambrose PG, Jones RN. Pharmacodynamics in the evaluation of drug regimens. Ann Pharmacother 2002; 36(3):530-532.

Grasela TH. Cognitive Engineering - The tools, mindset, and strategy for an integrated development standard. Pharmaceutical News 2002; 9:87-93.

Grasela TH, Bhavnani SM. Geotherapeutics: changing the paradigm of global drug development. Pharmaceutical News 2002; 9:111-119.

Owens RC, Jr., Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002; 22(5):663-668.

Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45(10):2793-2797.

Drusano GL, Preston SL, Owens RC, Jr., Ambrose PG. Fluoroquinolone pharmacodynamics. Clin Infect Dis 2001; 33(12):2091-2096.

Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 2001; 3(2):131-140.

Nicolau DP, Ambrose PG. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med 2001; 111 Suppl 9A:13S-18S.

Ouslander JG, Maloney C, Grasela TH, Rogers L, Walawander CA. Implementation of a nursing home urinary incontinence management program with and without tolterodine. J Am Med Dir Assoc 2001; 2(5):207-214.

Phillips L, Grasela TH, Agnew JR, Ludwig EA, Thompson GA. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. Clin Pharmacol Ther 2001; 70(4):370-383.

Fleishaker JC, Fiedler-Kelly J, Grasela TH. Population pharmacokinetics of tirilazad: effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhage. Pharm Res 1999; 16(4):575-583.

Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 1999; 39(4):373-384.

Grasela TH, Antal EJ, Fiedler-Kelly J, Foit DJ, Barth B, Knuth DW et al. An automated drug concentration screening and quality assurance program for clinical trials. Drug Information Journal 1999; 33:273-279.

Wang EC, Grasela TH, Walawander CA. Applying epidemiology-based outcomes research to clinical decision-making. A hypothetical model of biotechnology therapy in gram-negative sepsis. Pharmacoeconomics 1999; 15(4):385-393.

Adams JM, Shelton MJ, Hewitt RG, Grasela TH, DeRemer M, Morse GD. Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients. Antimicrob Agents Chemother 1998; 42(4):821-826.

Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997; 17(4):729-736.

Schmith VD, Fiedler-Kelly J, Phillips L, Grasela TH, Jr. Dose proportionality of cisatracurium. J Clin Pharmacol 1997; 37(7):625-629.

Schmith VD, Fiedler-Kelly J, Phillips L, Grasela TH, Jr. Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracurium. Pharm Res 1997; 14(1):91-97.

Cullen DJ. The publication of commercially supported supplements statement. Anesth Analg 1995; 81(4):886-887.